Welcome to our dedicated page for Shineco SEC filings (Ticker: SISI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Shineco鈥檚 breakthrough physical extraction of water-soluble phospholipids may wow scientists, but it turns every 10-K into a maze of chemistry tables and R&D footnotes. If you have ever asked, 鈥淗ow do I find Shineco鈥檚 clinical trial costs or nutraceutical margins without reading 300 pages?鈥�, this page is the answer.
Stock Titan delivers AI-powered summaries that turn dense disclosures into clear insights. Our engine flags each Shineco insider trading Form 4 transactions alert, digests the entire Shineco annual report 10-K simplified, and highlights segment revenue so you can act quickly.
- AG真人官方-time push for Shineco Form 4 insider transactions real-time, including patent-related stock awards.
- Instant context around every Shineco quarterly earnings report 10-Q filing鈥擜I pulls phospholipid yield, diagnostic reagent sales, and cash burn ratios.
- Plain-English notes on each Shineco 8-K material events explained, whether it鈥檚 FDA feedback or a nutraceutical plant expansion.
Need deeper analysis? Use our tagged excerpts to compare deferred R&D tax credits across years or to monitor Shineco executive stock transactions Form 4 before material events. The platform also links the latest Shineco proxy statement executive compensation to peer benchmarks and delivers a concise Shineco earnings report filing analysis.
Stop scrolling through EDGAR PDFs. With Stock Titan you鈥檙e understanding Shineco SEC documents with AI鈥攆rom phospholipid IP disclosures to cash-flow swings鈥攕o you can focus on decisions, not data hunting.
Shineco has completed a significant acquisition of 51% equity stake in InfiniClone Limited, a Hong Kong-based company, on June 18, 2025. The transaction structure includes:
- Cash payment of US$19,895,600
- Issuance of 3,450,000 shares of Shineco common stock
The share issuance was conducted under Regulation S, confirming the seller, Dr. Lim Kah Meng, is not a U.S. person or resident. Following the acquisition, InfiniClone becomes a direct subsidiary of Shineco Life Science Group Hong Kong, a Shineco subsidiary.
The company will file required financial statements and pro forma financial information within 71 days of this report. This strategic acquisition represents a significant expansion of Shineco's business operations in Hong Kong, with potential implications for its market presence in Asia.
Shineco, Inc. (Nasdaq: SISI) has received a Nasdaq staff determination letter indicating non-compliance with the minimum bid-price rule and faces imminent trading suspension. The notice, dated 16 June 2025, cites failure to meet the US$1.00 bid-price requirement under Nasdaq Listing Rule 5550(a)(2). Because the company already executed a reverse stock split within the past 12 months, Rule 5810(c)(3)(A)(iv) renders it ineligible for an additional 180-day grace period.
Unless Shineco appeals, Nasdaq will suspend trading on 25 June 2025 and file Form 25-NSE to remove SISI from listing and registration. The company has until 23 June 2025 to request a hearing before Nasdaq鈥檚 Hearings Panel. Shineco states it will submit the hearing request; this automatically stays the suspension and any delisting action until the panel reaches a decision or grants additional time.
The company emphasizes that its underlying operations and the ability to trade its shares on other venues are currently unaffected by the letter. However, investors face heightened liquidity and pricing risk should Nasdaq ultimately delist the shares.
FAQ
What is the current stock price of Shineco (SISI)?
What is the market cap of Shineco (SISI)?
